Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
10 juin 2024 04h00 HE
|
Spherix Global Insights
EXTON, PA, June 10, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
Global Hemoglobinopathies Market is Expected to Reach $7.0 Billion by 2031: Says AMR
25 août 2022 08h33 HE
|
Allied Market Research
Portland, OR, Aug. 25, 2022 (GLOBE NEWSWIRE) -- The Global Hemoglobinopathies Market size was estimated at $4.2 billion in 2021 and is expected to hit $7.0 billion by 2031, registering a CAGR of...
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
04 juin 2021 07h00 HE
|
Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
Imara Reports First Quarter 2021 Financial Results and Business Highlights
11 mai 2021 07h00 HE
|
Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
04 mai 2021 07h00 HE
|
Imara, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara Announces Appointment of Stephen M. Migausky as General Counsel
04 mai 2020 07h00 HE
|
Imara, Inc.
BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
IMARA Announces Pricing of Initial Public Offering
11 mars 2020 21h57 HE
|
Imara, Inc.
BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...